| Title : Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation - Coe_2005_J.Med.Chem_48_3474 |
| Author(s) : Coe JW , Brooks PR , Vetelino MG , Wirtz MC , Arnold EP , Huang J , Sands SB , Davis TI , Lebel LA , Fox CB , Shrikhande A , Heym JH , Schaeffer E , Rollema H , Lu Y , Mansbach RS , Chambers LK , Rovetti CC , Schulz DW , Tingley FD, 3rd , O'Neill BT |
| Ref : Journal of Medicinal Chemistry , 48 :3474 , 2005 |
|
Abstract :
Herein we describe a novel series of compounds from which varenicline (1, 6,7,8,9-tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine) has been identified for smoking cessation. Neuronal nicotinic acetylcholine receptors (nAChRs) mediate the dependence-producing effects of nicotine. We have pursued alpha4beta2 nicotinic receptor partial agonists to inhibit dopaminergic activation produced by smoking while simultaneously providing relief from the craving and withdrawal syndrome that accompanies cessation attempts. Varenicline displays high alpha4beta2 nAChR affinity and the desired in vivo dopaminergic profile. |
| PubMedSearch : Coe_2005_J.Med.Chem_48_3474 |
| PubMedID: 15887955 |
Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, Shrikhande A, Heym JH, Schaeffer E, Rollema H, Lu Y, Mansbach RS, Chambers LK, Rovetti CC, Schulz DW, Tingley FD, 3rd, O'Neill BT (2005)
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation
Journal of Medicinal Chemistry
48 :3474
Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, Shrikhande A, Heym JH, Schaeffer E, Rollema H, Lu Y, Mansbach RS, Chambers LK, Rovetti CC, Schulz DW, Tingley FD, 3rd, O'Neill BT (2005)
Journal of Medicinal Chemistry
48 :3474